This Cal-Maine Foods Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday
Analysts downgraded UiPath, Cal-Maine with several price-target cuts.
Stocks · News reference
Goldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $19
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $32
Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $43 to $32.
JP Morgan Downgrades Ultragenyx Pharmaceutical to Neutral, Lowers Price Target to $36
JP Morgan analyst Anupam Rama downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Overweight to Neutral and lowers the price target from $80 to $36.